**Virtually all patients with metastatic breast cancer eventually develop resistance to first-line systemic therapy** , though the timeline and subsequent treatment patterns vary considerably by breast cancer subtype and initial treatment regimen.

## Resistance Rates by Treatment Line In a real-world cohort of 1,545 patients with HR+/HER2- metastatic breast cancer initiating first-line chemotherapy,

**57% subsequently required second-line chemotherapy, 31% required third-line, and 17% required fourth-line chemotherapy** .[1]

However, these percentages reflect only those who received subsequent chemotherapy during the study period and underestimate total progression rates, as many patients who progressed did not receive further treatment. The **clinical benefit rate (complete response + partial response + stable disease) progressively declines** with each treatment line. In one retrospective analysis, clinical benefit decreased from 85% at first-line to 54% at fourth-line chemotherapy.[2]

Response rates show even steeper declines: from 20% at first-line to 0% at fourth- line in this cohort.[2]

## Resistance Patterns by Subtype

**HR+/HER2- Disease:** For patients receiving first-line CDK4/6 inhibitor plus endocrine therapy, resistance inevitably develops in most patients despite approximately 20% achieving long-term disease control at five years.[3]

After CDK4/6 inhibitor progression, **only 40.5% of patients achieved at least 6 months of benefit from second-line therapy** .[4]

Notably, **61% of patients with progressive disease at first evaluation did not receive subsequent treatment** , suggesting either appropriate clinical judgment to avoid futility or potential undertreatment.[2] **Triple-Negative Breast Cancer:** The National Comprehensive Cancer Network guidelines outline sequential treatment options, but specific resistance rates are not well-quantified in the literature.[5] **HER2+ Disease:** Multiple lines of HER2-targeted therapy plus chemotherapy offer clinical benefit, though **the optimal sequence and true benefit beyond standard first and second lines remain unknown** , particularly after progression on pertuzumab-based chemotherapy and antibody-drug conjugates.[5]

## Survival by Treatment Line In HR+/HER2- metastatic breast cancer patients receiving chemotherapy,

**median overall survival from first-line chemotherapy start was 23.3 months** . For those receiving second, third, and fourth-line chemotherapy, median overall survival from each treatment initiation was **16.5 months, 11.8 months, and 9.1 months** , respectively.[1]

The **absence of at least 6 months of progression-free survival benefit with first-line therapy predicts reduced probability of benefit from subsequent lines** (OR: 0.39; 95% CI: 0.24-0.62, p[4]

Would you like me to summarize the latest evidence on molecular mechanisms of resistance in metastatic breast cancer, particularly focusing on how these mechanisms differ by subtype and how they inform selection of subsequent lines of therapy? This could help guide more personalized treatment strategies beyond standard sequencing.



### References
1. Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US). Tolaney S, Punie K, Kurian A, et al. Journal of Clinical Oncology. 2023;41(Suppl 16):e18871. doi:10.1200/JCO.2023.41.16_suppl.e18871.
2. What Is the Benefit of Treatment With Multiple Lines of Chemotherapy for Patients With Metastatic Breast Cancer? A Retrospective Cohort Study. Bakker JL, Wever K, van Waesberghe JH, et al. Cancer Epidemiology. 2015;39(6):848-53. doi:10.1016/j.canep.2015.09.010.
3. Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis. Buonaiuto R, Fordellone M, Caltavituro A, et al. EClinicalMedicine. 2025;89:103535. doi:10.1016/j.eclinm.2025.103535.
4. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. Bonotto M, Gerratana L, Iacono D, et al. The Oncologist. 2015;20(7):719-24. doi:10.1634/theoncologist.2015-0002.
5. Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16. 5.